These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18762759)

  • 1. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma.
    Drobyski WR; Hari P; Keever-Taylor C; Komorowski R; Grossman W
    Bone Marrow Transplant; 2009 Jan; 43(2):169-77. PubMed ID: 18762759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of severe cutaneous, GI and liver GVHD in a patient with multiple myeloma, status-post-second auto-SCT.
    Goddard DS; Ruben BS; Mathes ED; Nixon M; Wolf J; Fox LP
    Bone Marrow Transplant; 2010 Feb; 45(2):409-11. PubMed ID: 19597426
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Lazarus HM; Sommers SR; Arfons LM; Fu P; Ataergin SA; Kaye NM; Liu F; Kindwall-Keller TL; Cooper BW; Laughlin MJ; Creger RJ; Barr PM; Gerson SL; Kaplan D
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):970-8. PubMed ID: 21440080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eruption of lymphocyte recovery or autologous graft-versus-host disease?
    Nellen RG; van Marion AM; Frank J; Poblete-Gutiérrez P; Steijlen PM
    Int J Dermatol; 2008 Nov; 47 Suppl 1():32-4. PubMed ID: 18986483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
    Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
    Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect.
    Byrne JL; Carter GI; Ellis I; Haynes AP; Russell NH
    Bone Marrow Transplant; 1997 Sep; 20(6):517-20. PubMed ID: 9313888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft versus host disease in autologous stem cell transplantation.
    Marin GH; Porto A; Prates V; Napal J; Etchegogen O; Rubens L; Bordone J; Castelletto R; Buschiazzo H; Morales V; Milone J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):201-8. PubMed ID: 10464707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
    Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation.
    Messina G; Quartarone E; Console G; Cuzzola M; Iacopino O; Martino M; Irrera G; Morabito F; Iacopino P
    Haematologica; 2002 Jul; 87(7):ECR22. PubMed ID: 12091138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.